Catabasis Pharmaceuticals Inc (CATB): Deerfield Management Adds to Its Position

Page 5 of 12

Page 5 of 12 – SEC Filing
 
CUSIP No.
14875P107
13G
Page 5 of 9
 
1.
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
James E. Flynn
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
  (a) o
  (b) ý
3.
SEC USE ONLY
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
United States


NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
SOLE VOTING POWER
 
0
6.
SHARED VOTING POWER
 
783,375 (3)
7.
SOLE DISPOSITIVE POWER
 
0
8.
SHARED DISPOSITIVE POWER
 
783,375 (3)
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
783,375 (3)
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
o
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.21%
12.
TYPE OF REPORTING PERSON*
 
IN
    
__________________
(3) Comprised of shares of common stock held by Deerfield Special Situations Fund, L.P.

Follow Astria Therapeutics Inc. (NASDAQ:ATXS)

Page 5 of 12